These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
864 related articles for article (PubMed ID: 18005022)
1. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Gisondi P; Cotena C; Tessari G; Girolomoni G J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022 [TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. Briot K; Gossec L; Kolta S; Dougados M; Roux C J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782 [TBL] [Abstract][Full Text] [Related]
3. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Gerloni V; Pontikaki I; Gattinara M; Fantini F Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916 [TBL] [Abstract][Full Text] [Related]
4. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]
5. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515 [TBL] [Abstract][Full Text] [Related]
6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Wolfe F; Michaud K Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349 [TBL] [Abstract][Full Text] [Related]
7. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Saraceno R; Schipani C; Mazzotta A; Esposito M; Di Renzo L; De Lorenzo A; Chimenti S Pharmacol Res; 2008 Apr; 57(4):290-5. PubMed ID: 18400510 [TBL] [Abstract][Full Text] [Related]
8. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600 [TBL] [Abstract][Full Text] [Related]
9. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. Haitz KA; Kalb RE J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715 [TBL] [Abstract][Full Text] [Related]
10. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Galor A; Perez VL; Hammel JP; Lowder CY Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615 [TBL] [Abstract][Full Text] [Related]
11. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863 [TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803 [TBL] [Abstract][Full Text] [Related]
13. Body weight increment in patients treated with infliximab for plaque psoriasis. Florin V; Cottencin AC; Delaporte E; Staumont-Sallé D J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e186-90. PubMed ID: 22621415 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Mazzotta A; Esposito M; Costanzo A; Chimenti S Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444 [TBL] [Abstract][Full Text] [Related]
15. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383 [TBL] [Abstract][Full Text] [Related]
17. Etanercept combined with methotrexate for high-need psoriasis. Driessen RJ; van de Kerkhof PC; de Jong EM Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310 [TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Kakkassery V; Mergler S; Pleyer U Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052 [TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]